On April 29, 2025, the U.S. National Institutes of Health (NIH) announced the establishment of the Office of Research Innovation, Validation, and Application (ORIVA), a new office dedicated to advancing and coordinating the development, validation, and implementation of New Approach Methodologies (NAMs) across the NIH research portfolio. The creation of ORIVA represents a significant policy shift in biomedical research, reflecting increasing recognition of the limitations of animal models and the growing potential of human-relevant experimental systems.
According to Nicole Kleinstreuer, Ph.D., NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives, ORIVA aims to accelerate innovation and promote a systematic transition toward methodologies that reduce or replace animal use while improving human health outcomes. By establishing a centralized framework for evaluating and implementing NAMs, NIH seeks to promote a more predictive, efficient, and translationally relevant research ecosystem.
ORIVA is positioned within the NIH Office of the Director and is intended to serve as a coordinating body across all 27 NIH Institutes and Centers. Its primary mission is to facilitate the development, validation, and application of non-animal methodologies while promoting consistency in their adoption throughout the NIH-funded research enterprise.
A key component of ORIVA’s structure is its role in fostering interagency collaboration. By coordinating with regulatory agencies such as the U.S. Food and Drug Administration (FDA) and other federal partners, ORIVA aims to facilitate the translation of scientific innovations into regulatory practice and clinical applications.
One of ORIVA’s most significant initiatives involves modifications to the NIH funding and peer-review process. Under the new framework, research proposals are expected to be evaluated according to criteria that include scientific suitability, context of use, translational relevance, and human applicability.
The NIH has also announced a gradual transition away from funding opportunities that exclusively require animal models. Future funding announcements are expected to encourage or require the incorporation of human-relevant methodologies when scientifically appropriate. In addition, annual public reporting of research expenditures will provide transparency regarding progress toward increased adoption of NAMs.
These measures are designed to align funding priorities with emerging scientific evidence indicating that many traditional animal models demonstrate limited predictive value for human biology and clinical outcomes.
A notable aspect of ORIVA is its focus on reducing methodological bias within grant review systems. Historically, animal-based research approaches have often been viewed as the default standard in biomedical research evaluation.
To address this issue, NIH plans to implement reviewer training programs aimed at improving understanding of alternative methodologies and reducing potential bias against non-animal approaches. Furthermore, peer-review panels are expected to include experts with specialized knowledge in organoids, microphysiological systems, computational modeling, and other NAM-related technologies.
These initiatives are intended to ensure that proposals utilizing innovative methodologies are evaluated based on scientific merit rather than familiarity with traditional experimental models.
ORIVA's activities encompass a broad range of emerging technologies designed to improve the physiological relevance of biomedical research.
Human-Based Experimental Systems
Human-derived organoids, organ-on-chip platforms, and advanced three-dimensional culture systems represent key components of ORIVA’s technology portfolio. These models can recapitulate important aspects of human physiology, disease progression, and patient-specific variability that are difficult to reproduce in animal systems.
Computational and Artificial Intelligence Models
Advances in computational biology, machine learning, and artificial intelligence have enabled increasingly sophisticated simulations of biological processes. ORIVA supports the development of predictive models capable of evaluating disease mechanisms, drug responses, and toxicological outcomes while reducing reliance on animal experimentation.
Real-World Data and Human Evidence
The integration of clinical data, electronic health records, patient registries, and population-level datasets provides additional opportunities for generating evidence directly relevant to human health. ORIVA recognizes real-world data as an important complement to experimental research and computational modeling.
Potential Impact on Biomedical Research
The establishment of ORIVA may help address a long-standing challenge in biomedical science: the translation gap between preclinical findings and clinical success. Numerous studies have demonstrated that a substantial proportion of therapeutic candidates that show efficacy in animal models ultimately fail during human clinical trials.
By promoting human-relevant research platforms, ORIVA seeks to improve predictive accuracy and enhance the efficiency of drug discovery and development. Improved translational performance could reduce development costs, accelerate therapeutic innovation, and increase the likelihood of clinical success.
In addition, increased federal support for NAMs is expected to stimulate growth in biotechnology sectors focused on organoid technologies, organ-on-chip systems, computational toxicology, and artificial intelligence-driven drug development.
Regulatory and Global Implications
ORIVA's emphasis on regulatory translation has important implications for regulatory science. By facilitating communication between research institutions and regulatory agencies, the office may accelerate the acceptance of validated alternative methods for safety assessment and therapeutic evaluation.
The initiative also has international significance. Regulatory agencies and research organizations in Europe, Australia, and other regions are increasingly exploring strategies to reduce animal testing and expand the use of human-relevant methodologies. As the world's largest public funder of biomedical research, NIH may influence global standards and accelerate international adoption of NAM-based approaches.
Challenges and Future Perspectives
Despite its promise, several challenges remain. First, successful implementation will require substantial investment in validation studies to establish confidence in emerging methodologies. Second, widespread adoption of NAMs will necessitate workforce training, infrastructure development, and cultural adaptation within the scientific community. Third, the long-term impact of ORIVA will depend on sustained institutional support and adequate funding.
Furthermore, although NAMs offer significant advantages, they currently complement rather than completely replace animal research in many areas of biomedical investigation. Continued methodological innovation and rigorous validation will be essential for expanding their applications.
The establishment of ORIVA represents a major milestone in the evolution of biomedical research policy. By integrating human relevance into funding priorities, peer-review processes, infrastructure development, and regulatory translation, NIH has created a framework for accelerating the adoption of innovative research methodologies.
While significant scientific and operational challenges remain, ORIVA reflects a growing commitment to developing more predictive, efficient, and human-centered approaches to biomedical research. Its success may ultimately reshape how diseases are studied, therapies are developed, and scientific discoveries are translated into improved patient outcomes.
français 
Deutsch 
Español 
italiano 
русский 
português 
العربية 
Nederland